GILD Gilead Sciences Inc.

Gilead Sciences to Present at the Credit Suisse 25th Annual Healthcare Conference on Monday, November 7

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F. Milligan, PhD, Gilead’s President and Chief Executive Officer, will participate in a fireside chat at the Credit Suisse 25th Annual Healthcare Conference in Scottsdale, AZ on Monday, November 7 at 8:00 a.m. Mountain Time.

The audio portion of the fireside chat will be accessible live through the company’s Investors page at www.gilead.com/investors. Please connect to the company’s website at least 15 minutes prior to the start of the presentation to ensure adequate time for any software download that may be required to listen to the webcast. The replay will be available for 14 days following the presentation.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

EN
24/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Gilead Sciences Inc.

Gilead Sciences, Inc. - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Gilead Sciences Inc: 3 directors

Three Directors at Gilead Sciences Inc sold/sold after exercising options 20,611 shares at between 125.080USD and 127.105USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Downgrading Financials to Underweight We remain bullish since our 4/22/25 Compass, and we will maintain our bullish outlook as long as market dynamics remain healthy and the S&P 500 (SPX) is above 6028-6059. We would need to see a break below 6569 in order to have confidence that a consolidation period has finally begun. For now, we continue to expect support to show up at the 4-month uptrend, which generally coincides with the 20-day MA. Short-term supports to buy include 6640 (the 20-day MA),...

Moody's Ratings affirms Gilead's A3 rating; revises outlook to positiv...

Moody's Ratings (Moody's) affirmed the ratings of Gilead Sciences, Inc. ("Gilead") including the A3 senior unsecured ratings and (P)A3 senior unsecured shelf rating. At the same time, we revised the outlook to positive from stable. The positive outlook reflects positive momentum in Gilead's pipeli...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch